Abarca CEO: Drug Pricing to Follow Model Set by Medicare Drug Negotiations Going Forward

With the impending Medicare drug pricing negotiations in the next few years, the future of drug pricing is uncertain in the US. According to Jason Borschow, CEO of the pharmacy benefit manager (PBM) Abarca Health, thinks that the pricing model will be the default for the pharma and biotech industries going forward.

According to Borschow, “Even the biggest PBMs have no solution for these drugs that have no competition. And so who’s going to make the determination? We should find that balance where the government negotiation is limited to drugs that have no competition, and we allow the private markets to have more flexibility around determining what’s best for their area and for their region. That’s my hope”

To read more, click here.

(Source: Med City News, February 20^th, 2023)